MALDEN, MASS. (PRWEB) SEPTEMBER 27, 2022–Effective September 15, 2022 NANISX LLC, a spine medical device company excelling in developing less exposure surgery (LES) technologies in spine surgeries for ambulatory surgery centers (ASC) has announced that the firm has appointed former Medtronic, and Nuvasive sales executive, David Flickinger MBA as their new Chief Executive Officer (CEO).
“I couldn’t be more excited about the opportunity to build on the legacy and leadership of these KICVentures Group portfolio companies, NanoFuse Biologics, InSpan and Sacrix, now combined to be known as NANISX LLC. As an ever-greater number of spine procedures transition to the outpatient setting, we are among the first to focus our cutting-edge techniques and technologies for the ASC ecosystem to lead in improving less invasive care for patients. I’m looking forward to bringing the leadership and commercial expertise required for these therapies to reach their full potential.”
We’re looking to build out a team that shares both our vision and urgency to rapidly scale and execute on this incredible opportunity to improve patient lives. We are driven to build NANISX as the leading ASC spine company that develops world-class products plus delivers an unmatched physician to physician education experience which empowers rapid adoption of safe, effective, and highly reproducible procedures with great outcomes.
About David Flickinger
Mr. Flickinger has been in leadership positions at public companies such as Medtronic (MDT), Nuvasive (NUVA) and has held numerous sales leadership roles at Surgalign (SRGA) since its formation in 2020. He has proven experience in the spine and orthobiologics industry with influence on the buy and sell side of strategic mergers and acquisitions, management, development and deployment of strategic opportunities, the formation of distributor alliances and commercializing Coflex interspinous device and other innovative medical devices to the spine market.
Prior to a career in healthcare, David was an Infantry Officer in the United States Marine Corps, where he served as a Platoon Commander and Company Executive Officer with 3d Battalion 1st Marine Division. David was also the co-founder of Doc Social, a physician education and social media platform launched in December of 2020.
Watch David Flickinger MBA NANISX new CEO Introduction and Q&A Video
INVESTORS
Series A Now open in KICVentures Group.
With a revenue and EBITDA positive position from which to start, we are well-positioned to create tremendous value for investors, especially as we prepare for an IPO.
[email protected].
About NANISX LLC
NANISX LLC is privately owned by the KICVentures Group and is a spine medical device company excelling in developing less exposure surgery (LES) technologies in spine surgeries for ambulatory surgery centers (ASC). NANISX is formed from the merger of NanoFUSE Biologics LLC, Inspan LLC and Sacrix LLC. NANISX cross markets to Interventional Pain Management (IPM), Orthopedic spine surgeons and Neurosurgeons under NANISX Pain division and NANISX Ortho-Neuro division.
About NanoFUSE Biologics LLC
NanoFUSE Biologics LLC is privately owned by the KICVentures Group and has a proprietary fiber-based synthetic bioactive glass. NanoFUSE is the only FDA-approved combination of bioactive glass plus DBM and is proven for regenerating bone.
About InSpan LLC
InSpan LLC is privately owned by the KICVentures Group and is focused on advancing the platform of patented interspinous interlaminar fixation technology. The InSpan device has a proven ten-year track record with thousands implanted since FDA clearance in 2010. There are no documented device-related failures or spinous process fractures that have plagued other competitive ISP devices.
About Sacrix LLC
Sacrix LLC is privately owned by the KICVentures Group and is focused on revolutionary percutaneous fluoroscopic lateral-oblique sacroiliac joint fusion technologies for the treatment of sacroiliac dysfunction and sacroiliitis. Sacrix developed its patented Sacrofuse threaded implant to be inserted percutaneously and received FDA clearance in 2015. The Gen1 Sacrofuse implant was compared head-to-head with market leader SI bone (SIBN) and found to have a 400% increase in pull-out strength. Sacrix has trained over 200 physicians to perform its revolutionary percutaneous lateral-oblique sacroiliac joint fusion technique safely and effectively through a 1.5 cm incision minimally invasively in outpatient ambulatory surgery centers.
About KICVentures Group
Founded in 2000 makes us the most experienced healthcare investment holding company with the largest portfolio of medical device technologies focused on solutions for less invasive outpatient spine surgery. Our investment strategy is to acquire or invent disruptive technologies using our own capital or partner with private individual investors. This allows us the freedom to make quick and nimble decisions such as when we acquired AxioMed Viscoelastic Disc Technologies while other firms invested in ball-and-socket articulating spacers.